The role of surgery in advanced and recurrent ovarian cancer

Annals of Oncology

Volumn 17, Issue SUPPL. 10, 2006, Pages

  du Bois, A ^a   Harter, P ^a  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; FEMALE; GYNECOLOGIC SURGERY; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME;

FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS;

EID: 33749626972     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl266     Document Type: Article

References (47)

1. Covens AL. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 2000; 78: 269-274.
2. Meigs JV. Tumors of the Female Pelvic Organs. New York, NY: Macmillan 1934.
3. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcioma. Natl Cancer Inst Monogr 1975; 42: 101-104.
4. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study. Gynecol Oncol 1998; 69: 103-108.
5. Heintz APM, Hacker NF, Berelk JS et al. Cytoreductive surgery in ovarian carcinoma: Feasibility and morbidity. Obstet Gynecol 1986; 67: 783-788.
6. Piver MS, Baker T. The potential for optimal (≤2 cm) cytoreducitve surgery in advanced ovarian carcinoma at a tertiary medical center. A prospective study. Gynecol Oncol 1986; 24: 1-8.
7. Piver MS, Lele SB, Marchetti DL et al. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Clin Oncol 1988; 6: 983-989.
8. Bertelsen K. Tumor reduction surgery and long-term survival in advanced ovarian cancer: A DACOVA study. Gynecol Oncol 1990; 38: 203-209.
9. Hoskins WJ, Bundy BN, Thigpen JT et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 1992; 47: 159-166.
10. Hacker NF, Berek JS, Lagasse LD, Omura GA. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983; 61: 413-420.
11. Guldozzi F, Ball JHS. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 1994; 53: 326-330.
12. Allen DG, Heintz APM, Touw FWMM. A meta-analysis of residual disease and survival in stage III and IV carcinoma on the ovary. Eur J Gynaecol Oncol 1995; 16: 349-356.
13. Bristow RE, Tomacruz RS, Armstrong DK et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002; 20: 1248-1259.
14. Van der Burg MEL, van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995; 332: 629-634.
15. Rose PR, Nerenstone F, Brady MS et al. Secondary surgical cytoreduction for advanced ovarian carcinoma N Engl J Med 2004; 351: 2489-2497.
16. du Bois A, Rochon J, Lamparter C, Pfisterer J. Pattern of care and impact of participation in clinical studies on the outcome of ovarian cancer. Int J Gynecol Cancer 2005; 15: 183-190.
17. du Bois A, Quinn M, Thigpen T et al. 2004 consensus statements on the management of ovarian cancer: Final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005; 16 (Suppl 18): Viii7-viii12.
18. Panici PB, Maggloni A, Hacker N et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: A randomzed clinical trial. J Natl Cancer Inst 2005; 97: 560-566.
19. Chambers SK. Systematic lymphadenectomy in advanced epithelial ovarian cancer: Two decades of uncertainty resolved. J Natl Cancer Inst 2005; 97: 548-549.
20. Crawford CS, Vasey PA, Paul J et al. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 trial. J Clin Oncol 2005; 23: 8802-8811.
21. Sharp F, Blackett AD, Leake RE, Berek JS. Conclusions and recommendations from the Helene Harris Memorial Trust fifth biennial international forum on ovarian cancer, 4-7 May 1995, Glasgow UK. Int J Gynecol Cancer 1995; 5: 449-458.
22. Berek JS, Tropé C, Vergote I. Surgery during chemotherapy and at relapse of ovarian cancer. Ann Oncol 1999; 10 (Suppl 1): 3-7.
23. Cormio G, di Vagno G, Cazzolla A et al. Surgical treatment of recurrent ovarian cancer: Report of 21 cases and a review of the literature. Eur J Obstet Gynecol Reprod Biology 1999; 86: 185-188.
24. Elsenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer 2000; 88: 144-153.
25. Gadduci A, Iacconi P, Cosio S et al. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol 2000; 79: 344-349.
26. Gronlund B, Lundvall L, Christensen IJ et al. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete reponse to paclitaxel-platinum. Eur J Surgical Oncology 2005; 31: 67-73.
27. Güngör M, Ortac F, Arvas M et al. The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecol Oncol 2005; 97: 74-79.
28. Harter P, Hasenburg A, Burges A et al. Pre-operative selection criteria for operability in recurrent ovarian cancer. A study of the AGO Organkommission Ovar and the AGO Ovarian Cancer Study Grou (AGO-OVAR). Proc Am Soc Clin Oncol. 2005; 23 (Suppl 1): Abstr 5004.
29. Jaenicke F, Holscher M, Kuhn W et al. Radical surgery procedure improves survival time in patients with recurrent ovarian cancer. Cancer 1992; 70: 2129-2136.
30. Kuhn W, Schmalfeldt B, Pache L et al. Disease-adapted relapse therapy for ovarian cancer: Results of a prospective study. Int J Oncol 1998; 13: 57-63.
31. Leitao MM, Kardos S, Barakat RR, Chi DS. Tertiary cytoreduction in patients with recurrent ovarian cancer. Gynecol Oncol 2004; 95: 181-185.
32. Loehr A, Harter P, Traut A et al. Cytoreductive surgery in recurrent ovarian cancer. J Cancer Res Clin Oncol 2004; 130 (Suppl 1): 122 (Abstr OP570).
33. Morris M, Gershenson DM, Wharton JT et al. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol 1989; 34: 334-338.
34. Munkarah A, Levenback C, Wolf JK et al. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer. Gynecol Oncol 2001; 81: 237-241.
35. Onda T, Yoshikawa H, Yasugi T et al. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: Proposal for patients selection. Br J Cancer 2005; 92: 1026-1032.
36. Pecorelli SP, Sartori E, Santin A. Follow-up after primary therapy: management of the symptmatic patient surgery. Gynecol Oncol 2001; 81: 138-142.
37. Scarabelli C, Gallo A, Carbone A. Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 2001; 83: 504-512.
38. Tay EH, Grant PT, Gebski V, Hacker NF. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gynecol 2002; 99: 1008-1013.
39. Vaccarello L, Rubin SC, Vlamis V et al. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol Oncol 1995; 57: 61-65.
40. Zang RY, Zhang ZY, Li ZY et al. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J Surg Oncol 2000; 75: 24-30.
41. Zang RY, Li ZT, Tang J et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: Who benefits? Cancer 2004; 100: 1152-1161.
42. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplation compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
43. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimalley resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194-3200.
44. Piccart MJ, Bertelsen K, James K et al. Randomized Intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophospahmide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 2000; 92: 699-708.
45. du Bois A, Lueck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-1329.
46. Parmar MK, Ledermann A Colombo N et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-2106.
47. Pfisterer J, Plante M, Vergate I et al. Gemcitabine/carboplatin versus carboplatin in platinum sensitive recurrent ovarian cancer. Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. Proc Am Soc Clin Oncol 2004; 23: 449 (Abstr 5005).